Critical roles of DMP1 in human epidermal growth factor receptor 2/neu-Arf-p53 signaling and breast cancer development

Cancer Research

Volumn 70, Issue 22, 2010, Pages 9084-9094

  Taneja, Pankaj ^a   Maglic, Dejan ^a   Kai, Fumitake ^a   Sugiyama, Takayuki ^a   Kendig, Robert D ^a   Frazier, Donna P ^a   Willingham, Mark C ^a   Inoue, Kazushi ^a  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARF PROTEIN; DENTIN MATRIX PROTEIN 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MDM2; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL; CARCINOGENESIS; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION;

ANIMALS; BASE SEQUENCE; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; CELLS, CULTURED; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; EPITHELIAL CELLS; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78549234103     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-0159     Document Type: Article

References (48)

1. Ross JS, Hortobagyi GN. Molecular Oncology of Breast Cancer. Sudbury (MA): Jones and Bartlett Publishers; 2005.
2. Jemal A, Siegel R, Ward E, Hao Y, Thun MJ. Cancer statistics, 2009. Cancer J Clin 2009;59:225-49.
3. Morrow PK, Hortobagyi GN. Management of breast cancer in the genome era. Annu Rev Med 2009;60:153-65.
4. Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine. Expert Rev Mol Diagn 2003;3:573-85.
5. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
6. Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003;284:99-110.
7. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of target inhibitors. Nat Rev Cancer 2005;5:341-54.
8. Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986;319:230-4.
9. Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 2003;30:38-48.
10. Citri A, Skaria KB, Yarden Y. The deaf and dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 2003;284:54-65.
11. Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008;132:344-62.
12. Liu M, Ju X, Willmarth NE, et al. Nuclear factor-κB enhances ErbB2-induced mammary tumorigenesis and neoangiogenesis in vivo. Am J Pathol 2009;174:1910-20.
13. Pratt MA, Tobbo E, Robertson SJ, et al. The canonical NF-κB pathway is required for formation of luminal mammary neoplasias and is activated in the mammary progenitor population. Oncogene 2009;28: 2710-22.
14. Biswas DK, Singh S, Shi Q, Pardee AB, Iglehart JD. Crossroads of estrogen receptor and NF-κB signaling. Sci STKE 2005;2005:e27.
15. Hirai H, Sherr CJ. Interaction of D-type cyclins with a novel myb-like transcription factor, DMP1. Mol Cell Biol 1996;16:6457-67.
16. Inoue K, Sherr CJ. Gene expression and cell cycle arrest mediated by transcription factor DMP1 is antagonized by D-type cyclins through a cyclin-dependent-kinase-independent mechanism. Mol Cell Biol 1998;18:1590-600.
17. Inoue K, Roussel MF, Sherr CJ. Induction of ARF tumor suppressor gene expression and cell cycle arrest by transcription factor DMP1. Proc Natl Acad Sci U S A 1999;96:3993-8.
18. Sherr CJ, Bertwistle D, den Besten W, et al. p53-dependent and -independent functions of the Arf tumor suppressor. Cold Spring Harbor Symp Quant Biol 2005;70:129-37.
19. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006;6:663-73.
20. Inoue K, Wen R, Rehg JE, et al. Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. Genes Dev 2000;14:1797-809.
21. Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev 2001;15:2934-9.
22. Sreeramaneni R, Chaudhry A, McMahon M, Sherr CJ, Inoue K. Ras-Raf-Arf signaling critically depends on the Dmp1 transcription factor. Mol Cell Biol 2005;25:220-32.
23. Mallakin A, Taneja P, Matise LA, Willingham MC, Inoue K. Expression of Dmp1 in specific differentiated, nonproliferating cells and its repression by E2Fs. Oncogene 2006;25:7703-13.
24. Taneja P, Mallakin A, Matise LA, Frazier DP, Choudhary M, Inoue K. Repression of Dmp1 and Arf transcription by anthracyclins: critical roles of the NF-κB subunit p65. Oncogene 2007;26:7457-66.
25. Inoue K, Mallakin A, Frazier DP. Dmp1 and tumor suppression. Oncogene 2007;26:4329-35.
26. Mallakin A, Sugiyama T, Taneja P, et al. Mutually exclusive inactivation of DMP1 and ARF/p53 in lung cancer. Cancer Cell 2007;12: 381-94.
27. Inoue K, Sugiyama T, Taneja P, Morgan RL, Frazier DP. Emerging roles of DMP1 in lung cancer. Cancer Res 2008;68:4487-90.
28. Sugiyama T, Frazier DP, Taneja P, Morgan RL, Willingham MC, Inoue K. Role of DMP1 and its future in lung cancer diagnostics. Expert Rev Mol Diagn 2008;8:435-47.
29. Bodner SM, Naeve CW, Rakestraw KM, et al. Cloning and chromosomal localization of the gene encoding human cyclin D-binding Myb-like protein (hDMP1). Gene 1999;229:223-8.
30. Tschan MP, Fisher KM, Fung VS, et al. Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J Biol Chem 2003;278:42750-60.
31. BiecheI,ChampemeMH,MatifasF,HaceneK,CallahanR,LindereauR. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 1992;339:139-43.
32. Kristjansson AK, Eiriksdottir G, Ragnarsson G, et al. Loss of heterozygosity at chromosome 7q in human breast cancer: association with clinical variables. Anticancer Res 1997;17:93-8.
33. Casalini P, Botta L, Menard S. Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem 2001;276:12449-53.
34. Muller WJ, Sinn E, Pattengale PK, Wallace R, Leder P. Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 1988;54:105-15.
35. Amarante MK, Watanabe MA. The possible involvement of virus in breast cancer. J Cancer Res Clin Oncol 2009;135:329-37.
36. Wang Y, Holland JF, Bleiweiss IJ, et al. Detection of mammary tumor virus env gene-like sequences in human breast cancer. Cancer Res 1995;55:5173-9.
37. Mallakin A, Sugiyama T, Kai F, et al. The Arf-inducing transcription factor Dmp1 encodes transcriptional activator of amphiregulin, thrombospondin-1, JunB and Egr1. Int J Cancer 2010;126: 1403-16.
38. Yang X, Edgerton SM, Kosanke SD, et al. Hormonal and dietary modulation of mammary carcinogenesis in mouse mammary tumor virus-c-erbB-2 transgenic mice. Cancer Res 2003;63:2425-33.
39. Faltus T, Yuan J, Zimmer B, et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004;6: 786-95.
40. Perkins ND. Post-translational modifications regulating the activity and function of the nuclear factor κ B pathway. Oncogene 2006; 25:6717-30, Review.
41. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-κ B. Mol Cell 2004;13:853-65.
42. Rocha S, Garrett MD, Campbell KJ, Schumm K, Perkins ND. Regulation of NF-κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor. EMBO J 2005;24:1157-69.
43. Zhang Y, Yang HY, Zhang XC, Yang H, Tsai M, Lee MH. Tumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growth. Oncogene 2004;23:7132-43.
44. Bertwistle D, Sherr CJ. Regulation of the Arf tumor suppressor in Emicro-Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis. Blood 2007;109:792-4.
45. Rowley M, Grothey E, Couch FJ. The role of Tbx2 and Tbx3 in mammary development and tumorigenesis. J Mammary Gland Biol Neoplasia 2004;9:109-18.
46. Davis E, Teng H, Bilican B, et al. Ectopic Tbx2 expression results in polyploidy and cisplatin resistance. Oncogene 2008;27:976-84.
47. Agrawal A, Yang J, Murphy RF, Agrawal DK. Regulation of the p14ARF-Mdm2-53 pathway: an overview in breast cancer. Exp Mol Pathol 2006;81:115-22.
48. Ohtani N, Zebedee Z, Huot TJ, et al. Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 2001;409:1067-70.